Alkermes Stock Gaps Up On Today's Open (ALKS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Shares of Alkermes (Nasdaq: ALKS) were gapping up Wednesday morning with an open price 10.1% higher than Tuesday's closing price. The stock closed at $25.60 Tuesday and opened today's trading at $28.19.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The average volume for Alkermes has been 1.2 million shares per day over the past 30 days. Alkermes has a market cap of $3.26 billion and is part of the health care sector and drugs industry. Shares are up 30.8% year to date as of the close of trading on Tuesday.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes.

TheStreet Ratings rates Alkermes as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Alkermes Ratings Report.

Get more investment ideas from our investment research center.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Alkermes Is Getting Ready for a Rally

Alkermes Is Getting Ready for a Rally

Alkermes: Cramer's Top Takeaways

Alkermes: Cramer's Top Takeaways

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Jobs Report Just Right for Stocks: Cramer's 'Mad Money' Recap (Friday 12/8/17)

Jobs Report Just Right for Stocks: Cramer's 'Mad Money' Recap (Friday 12/8/17)

Nucor, Alkermes, T-Mobile, Axon Enterprise: 'Mad Money' Lightning Round

Nucor, Alkermes, T-Mobile, Axon Enterprise: 'Mad Money' Lightning Round